ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer - PubMed (original) (raw)

Review

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer

D E Gerber et al. Clin Pharmacol Ther. 2015 May.

Abstract

The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.

© 2015 American Society for Clinical Pharmacology and Therapeutics.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Dramatic therapeutic effects of molecularly targeted therapies demonstrated in serial axial chest computed tomography images. (a) Radiographic response to epidermal growth factor receptor (EGFR) inhibition in patient with EGFR mutant non-small cell lung cancer (NSCLC) after 2 mo of treatment. (b) Ongoing radiographic response to anaplastic lymphoma kinase (ALK) inhibition in patient with ALK rearranged NSCLC after 6 mo of treatment.

Figure 2

Figure 2

ALCHEMIST schema.

Similar articles

Cited by

References

    1. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011;3:75ra26. - PMC - PubMed
    1. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am. Soc. Clin. Oncol. Educ. Book. 2014:e353–e365. - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008;26:3552–3559. - PubMed
    1. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J. Clin. Oncol. 2014;32:780–787. - PubMed
    1. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK 1 lung adenocarcinoma. J. Thorac. Oncol. 2012;7:90–97. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources